The Indian pharmaceutical sector is strategically poised to capitalize on the recent healthcare initiatives introduced by President Donald Trump, aimed at enhancing the affordability and accessibility of medical treatments in the United States. This development presents significant opportunities for Indian drug manufacturers to expand their